Skip to main content
Cipla Ltd. logo

Cipla Ltd. — Investor Relations & Filings

Ticker · CIPLA ISIN · INE059A01026 LEI · 335800KMJJYEDDK82Q34 BSE.NS Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2026-05-13 Board/Management Inform…
Country IN India
Listing BSE.NS CIPLA

About Cipla Ltd.

https://www.cipla.com/

Cipla Ltd. is a global pharmaceutical company focused on the development, manufacturing, and marketing of a wide range of generic and branded medicines. The company maintains a diverse portfolio of over 1,500 products across various therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system treatments. It is recognized for its leadership in respiratory care and its historical role in making HIV/AIDS treatment affordable through the introduction of low-cost antiretroviral drugs. Operating with a strong emphasis on research and development, the firm utilizes advanced technology to produce complex generics and drug delivery systems. Its global footprint spans multiple continents, serving healthcare providers and patients in numerous international markets through a robust supply chain and manufacturing infrastructure.

Recent filings

Filing Released Lang Actions
Grant of stock options and employee stock appreciation rights (ESARs)
Board/Management Information Classification · 90% confidence The document is an outcome of a Board meeting under SEBI Regulations, announcing corporate governance decisions: convening the AGM, approving ESOP/ESAR grants, appointing cost auditors, and appointing a senior management personnel. This clearly falls under announcement of board/management changes and information, matching the Board/Management Information category.
2026-05-13 English
Updates
Board/Management Information Classification · 85% confidence The document is an ‘Outcome of the Board meeting’ notice under SEBI Listing Regulations, detailing the Board’s decisions on convening the AGM, granting stock options, appointing cost auditors, and appointing a new senior management personnel. It is not a full financial report but an announcement of management and governance changes arising from the Board meeting. This fits the Board/Management Information category (MANG).
2026-05-13 English
Appointment of Cost Auditor
Board/Management Information Classification · 85% confidence The document is a Regulation 30 disclosure under SEBI Listing Regulations detailing the outcome of a Board meeting. It announces the convening of the AGM, grants under the stock option schemes, appointment of cost auditors, and, crucially, the appointment of a senior management executive (Mr. Sushrut Kulkarni). This falls squarely under announcements of changes in the company’s board or senior management.
2026-05-13 English
Appointment
Board/Management Information Classification · 93% confidence The document is an official disclosure under SEBI Listing Regulations announcing the outcome of a Board meeting held on 13 May 2026, including the approval of convening the AGM, grant of stock options, appointment of cost auditors, and appointment of a senior management executive. This is a direct announcement of changes in management and board‐related decisions, fitting the Board/Management Information category.
2026-05-13 English
Appointment of Mr Sushrut Kulkarni as Senior Management Personnel of the Company w.e.f 18 May 2026
Board/Management Information Classification · 90% confidence The document is a SEBI Regulation 30 disclosure announcing the outcome of a Board meeting on May 13, 2026, which includes approval of the AGM date, stock option grants, appointment of cost auditors, and the appointment of a new Senior Management Personnel. This is a typical board/management change announcement rather than a full financial report or earnings release.
2026-05-13 English
Appointment
Board/Management Information Classification · 95% confidence The document is an official announcement of the outcomes of a Board meeting held on May 13, 2026, under SEBI LODR Regulation 30, detailing (i) convening of the AGM, (ii) stock option grants, (iii) appointment of cost auditors, and (iv) appointment of a senior management executive. Such notices of board decisions—particularly management and board level appointments—fall under ‘Board/Management Information’ (MANG).
2026-05-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.